Crucell

ICON appoints two in Asia Pacific operations

Monday, October 26, 2015

ICON, a global provider of drug development solutions and services to the pharmaceutical, biotechnology and medical device industries, has announced two new leadership appointments to its Asia Pacific operations. Mary Pan has been appointed vice president, Asia Pacific, where she will lead ICON’s continued growth and expansion in the region. Hiroshi Ichikawa has been appointed vice president and general manager of ICON’s operations in Japan.

[Read More]

J&J begins Ebola vaccine regimen in Sierra Leone

Monday, October 19, 2015

Johnson & Johnson (J&J) has begun a safety and immunogenicity clinical trial in Sierra Leone of a preventive Ebola vaccine regimen in development at its Janssen Pharmaceutical Companies. Trial recruitment is underway, and the first volunteers have received their initial vaccine dose. It is the first study conducted of Janssen’s Ebola prime-boost vaccine regimen in a West African country affected by the recent Ebola epidemic.

[Read More]

Johnson & Johnson begins phase I clinical trial of Ebola vaccine regimen

Thursday, January 8, 2015

Johnson & Johnson has begun a phase I, first-in-human clinical trial of a preventive Ebola vaccine in development at its Janssen Pharmaceutical Companies. The trial is being led by the Oxford Vaccine Group, part of the University of Oxford Department of Pediatrics. Recruitment in the trial is underway, and the first volunteers have received their initial vaccine dose. Enrollment is expected to be completed by the end of January.

[Read More]

Johnson & Johnson to speed Ebola vaccine development, expand production

Thursday, October 23, 2014

Johnson & Johnson has made a commitment of up to $200 million to accelerate and significantly expand the production of an Ebola vaccine program in development at Janssen Pharmaceutical Companies. The company is closely collaborating with the World Health Organization (WHO), the National Institute of Allergy and Infectious Diseases (NIAID), as well as other key stakeholders, governments and public health authorities on the clinical testing, development, production and distribution of the vaccine regimen.

[Read More]

Trial Results: Immunology/Infectious Disease

Tuesday, October 7, 2008

Crucell and Sanofi Pasteur reported positive preliminary results from a phase II trial of CL-184, a vaccine for the treatment of rabies. This randomized, single-blind, controlled study enrolled 140 healthy subjects in the United States. The subjects received CL-184, a currently marketed human rabies immune globulin (HRIG) or placebo plus rabies vaccine.

[Read More]